ANI PHARMACEUTICALS, INC Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost
ANI PHARMACEUTICALS, INC (ANIP) had Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost of $8.43 million as of 2025-12-31, per its 10-K filed 2026-02-27.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross › Deferred Tax Assets, Tax Deferred Expense
us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost · last filed 2026-02-27
- 2025-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $8.43M.
- 2024-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $7.37M.
- 2023-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $6.01M.
- 2022-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $6.04M.
| Period end | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost |
|---|---|
| 2025-12-31 | $8.43M 10-K · filed 2026-02-27 |
| 2024-12-31 | $7.37M 10-K · filed 2026-02-27 |
| 2023-12-31 | $6.01M 10-K · filed 2025-02-28 |
| 2022-12-31 | $6.04M 10-K · filed 2024-02-29 |
| 2021-12-31 | $5.11M 10-K · filed 2023-03-09 |
| 2020-12-31 | $4.28M 10-K · filed 2022-03-15 |
| 2019-12-31 | $3.75M 10-K · filed 2021-03-11 |
| 2018-12-31 | $0.00 10-K · filed 2020-02-27 |
| 2012-12-31 | $3.03M 10-K · filed 2013-02-28 |
| 2011-12-31 | $2.75M 10-K · filed 2013-02-28 |
| 2010-12-31 | $2.31M 8-K · filed 2013-01-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |